» Articles » PMID: 24719332

The Protein Phosphatase 2A Regulatory Subunit B56γ Mediates Suppression of T Cell Receptor (TCR)-induced Nuclear Factor-κB (NF-κB) Activity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2014 Apr 11
PMID 24719332
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

NF-κB is an important transcription factor in the immune system, and aberrant NF-κB activity contributes to malignant diseases and autoimmunity. In T cells, NF-κB is activated upon TCR stimulation, and signal transduction to NF-κB activation is triggered by a cascade of phosphorylation events. However, fine-tuning and termination of TCR signaling are only partially understood. Phosphatases oppose the role of kinases by removing phosphate moieties. The catalytic activity of the protein phosphatase PP2A has been implicated in the regulation of NF-κB. PP2A acts in trimeric complexes in which the catalytic subunit is promiscuous and the regulatory subunit confers substrate specificity. To understand and eventually target NF-κB-specific PP2A functions it is essential to define the regulatory PP2A subunit involved. So far, the regulatory PP2A subunit that mediates NF-κB suppression in T cells remained undefined. By performing a siRNA screen in Jurkat T cells harboring a NF-κB-responsive luciferase reporter, we identified the PP2A regulatory subunit B56γ as negative regulator of NF-κB in TCR signaling. B56γ was strongly up-regulated upon primary human T cell activation, and B56γ silencing induced increased IκB kinase (IKK) and IκBα phosphorylation upon TCR stimulation. B56γ silencing enhanced NF-κB activity, resulting in increased NF-κB target gene expression including the T cell cytokine IL-2. In addition, T cell proliferation was increased upon B56γ silencing. These data help to understand the physiology of PP2A function in T cells and the pathophysiology of diseases involving PP2A and NF-κB.

Citing Articles

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.

Clark M, Lu R, Ho W, Dias M, Bernards R, Forman S Mol Oncol. 2024; 18(10):2333-2337.

PMID: 38932511 PMC: 11459031. DOI: 10.1002/1878-0261.13687.


Protein Phosphatase 2A: Role in T Cells and Diseases.

Roy S, Batra L J Immunol Res. 2023; 2023:4522053.

PMID: 37234102 PMC: 10208765. DOI: 10.1155/2023/4522053.


Evolutionary Conservation of PP2A Antagonism and G2/M Cell Cycle Arrest in Maedi-Visna Virus Vif.

Luperchio A, Jonsson S, Salamango D Viruses. 2022; 14(8).

PMID: 36016323 PMC: 9413702. DOI: 10.3390/v14081701.


PP2A and Its Inhibitors in Helper T-Cell Differentiation and Autoimmunity.

Khan M, Kalim U, Khan M, Lahesmaa R Front Immunol. 2022; 12:786857.

PMID: 35069561 PMC: 8766794. DOI: 10.3389/fimmu.2021.786857.


Demystifying Cell Cycle Arrest by HIV-1 Vif.

Salamango D, Harris R Trends Microbiol. 2021; 29(5):381-384.

PMID: 33478820 PMC: 8416294. DOI: 10.1016/j.tim.2021.01.001.


References
1.
Deichmann M, Polychronidis M, Wacker J, Thome M, Naher H . The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Res. 2001; 11(6):577-85. DOI: 10.1097/00008390-200112000-00004. View

2.
Acuto O, Di Bartolo V, Michel F . Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol. 2008; 8(9):699-712. DOI: 10.1038/nri2397. View

3.
Yang J, Fan G, Wadzinski B, Sakurai H, Richmond A . Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001; 276(51):47828-33. PMC: 2665282. DOI: 10.1074/jbc.M106103200. View

4.
Weyd H, Abeler-Dorner L, Linke B, Mahr A, Jahndel V, Pfrang S . Annexin A1 on the surface of early apoptotic cells suppresses CD8+ T cell immunity. PLoS One. 2013; 8(4):e62449. PMC: 3640057. DOI: 10.1371/journal.pone.0062449. View

5.
Hayden M, West A, Ghosh S . NF-kappaB and the immune response. Oncogene. 2006; 25(51):6758-80. DOI: 10.1038/sj.onc.1209943. View